HERIZON-BTC-302: A phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC) Meeting Abstract
| Authors: | Macarulla Mercade, T.; Harding, J. J.; Pant, S.; Wu, X.; Garfin, P.; Okusaka, T. |
| Abstract Title: | HERIZON-BTC-302: A phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sept 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S237 |
| Language: | English |
| ACCESSION: | WOS:001326612900062 |
| DOI: | 10.1016/j.annonc.2024.08.2078 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 62TiP -- Source: Wos |
